<DOC>
	<DOCNO>NCT00644761</DOCNO>
	<brief_summary>Open-label pharmacokinetic drug interaction study .</brief_summary>
	<brief_title>PK Study Tacrolimus Cyclosporine When Co-Administered With Adefovir Dipivoxil Post-Liver Transplant Patients</brief_title>
	<detailed_description>Multi-center , phase 2 , open-label , sequential-cohort , drug interaction study . Cohort 1 subject ( tacrolimus adefovir dipivoxil ) enrol first . Based finding Cohort 1 , decision make whether enroll subject Cohort 2 ( cyclosporine adefovir dipivoxil ) ( i.e. , interaction observe Cohort 1 , Cohort 2 subject would enrol ) . Since pharmacokinetic interaction observe Cohort 1 , Cohort 2 enrol .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<criteria>1865 year age Greater equal 6 month postliver transplantation Must document stable total daily dose tacrolimus cyclosporine three month . Must calculate creatinine clearance great equal 50 mL/min ( CockcroftGault method ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Hepatitis B</keyword>
	<keyword>Post-Liver Transplantation</keyword>
	<keyword>Adefovir Dipivoxil</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Cyclosporine</keyword>
</DOC>